Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661457 | 0.89 | MRGPRX4 (0.61) | MRGPRX4SCN9ASCN5AMAPTKDM4E | |
| SCHEMBL365526 | 0.84 | SCN9A (0.54) | SCN9A | |
| SCHEMBL679763 | 0.84 | SCN9A (0.64) | SCN9ASCN5A | |
| SCHEMBL371116 | 0.82 | SCN9A (0.67) | SCN9ASCN5APTPN1 | |
| SCHEMBL10659795 | 0.81 | TDP1 (0.60) | MRGPRX4SCN9AMAPTMCL1 | |
| SCHEMBL680717 | 0.81 | MAPK14 (0.56) | MRGPRX4SCN9ASCN5AMAPTKDM4E | |
| SCHEMBL680618 | 0.80 | MAPK14 (0.54) | SCN9A | |
| SCHEMBL5427673 | 0.80 | MRGPRX4 (0.70) | MRGPRX4SCN9ASCN5AMAPTKDM4E | |
| SCHEMBL680193 | 0.80 | MRGPRX4 (0.61) | MRGPRX4SCN9ASCN5APTPN1 | |
| SCHEMBL16319452 | 0.80 | SCN9A (0.66) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | MRGPRX4 344/4885SCN9A 13/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.